PA) -- Dr. Erle S. Robertson has been appointed
Leader of the Tumor Virology Program at the Abramson
Cancer Center of the University of Pennsylvania as well
as Associate Professor in Microbiology at the University
of Pennsylvania School of Medicine.
After receiving his doctorate in Microbiology and Molecular
Genetics at Wayne State University, Detroit, Robertson
became a fellow in microbiology and molecular genetics
at Harvard Medical School. He continued his research
pursuits as a fellow of the Cancer Research Institute
and a Leukemia Society of America special fellow at
Brigham and Women's Hospital.
Prior to coming to Penn, Robertson was an instructor
in the Department of Medicine at Harvard Medical School
and an Associate Professor of Microbiology and Immunology
at the University of Michigan Medical School, Ann Arbor.
During this time he designed many of the courses he
taught and was actively involved in the supervision
of graduate and post-graduate research projects.
Robertson's current research interests center around
identifying the mechanisms by which tumor viruses -
specifically the Epstein-Barr virus and Kaposi's sarcoma-associated
herpes virus - infect human cells and advance the development
of cancers, including Hodgkin's disease, Kaposi's sarcoma
and AIDS lymphoma; and looks forward to a time when
his research will advance to the point where specific
therapies will be developed for treating viral associated
Robertson has authored numerous articles, books, book
chapters, reviews and manuals; and has presented his
work at professional meetings, both nationally and internationally.
He is a member of Phi Beta Kappa and has received many
prestigious awards, including the First Investigator
from the National Cancer Institute is 1996, and the
Scholar Award from the Leukemia and Lymphoma Society
of America in 1999. He is a member of several professional
organizations, including the American Association for
the Advancement of Sciences, the Molecular Medicine
Society, the American Society of Virology and the American
Society for Microbiology. He is also on the editorial
boards of the two leading virology journals. Robertson
serves nationally on a number of scientific review panels
for the National Institutes of Health, and internationally
for the Scottish Hospital Endowments Research Trusts,
the Welcome Foundation and the Israel Science Foundation.
# # #
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.